Read by QxMD icon Read

Jason konner

Catherine A Shu, Malcolm C Pike, Anjali R Jotwani, Tara M Friebel, Robert A Soslow, Douglas A Levine, Katherine L Nathanson, Jason A Konner, Angela G Arnold, Faina Bogomolniy, Fanny Dao, Narciso Olvera, Elizabeth K Bancroft, Deborah J Goldfrank, Zsofia K Stadler, Mark E Robson, Carol L Brown, Mario M Leitao, Nadeem R Abu-Rustum, Carol A Aghajanian, Joanne L Blum, Susan L Neuhausen, Judy E Garber, Mary B Daly, Claudine Isaacs, Rosalind A Eeles, Patricia A Ganz, Richard R Barakat, Kenneth Offit, Susan M Domchek, Timothy R Rebbeck, Noah D Kauff
Importance: The link between BRCA mutations and uterine cancer is unclear. Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations (BRCA+ women), the role of concomitant hysterectomy is controversial. Objective: To determine the risk for uterine cancer and distribution of specific histologic subtypes in BRCA+ women after RRSO without hysterectomy. Design, Setting, and Participants: This multicenter prospective cohort study included 1083 women with a deleterious BRCA1 or BRCA2 mutation identified from January 1, 1995, to December 31, 2011, at 9 academic medical centers in the United States and the United Kingdom who underwent RRSO without a prior or concomitant hysterectomy...
June 30, 2016: JAMA Oncology
Katherine M Bell-McGuinn, Jason A Konner, William P Tew, Martee L Hensley, Alexia Iasonos, Eric Charpentier, Svetlana Mironov, Paul Sabbatini, Carol Aghajanian
OBJECTIVE: The aim of the study was to evaluate the activity and tolerability of iniparib monotherapy in women with BRCA1 or BRCA2-associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. METHODS AND MATERIALS: Eligible patients had advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, germline BRCA1 or BRCA2 mutation, measurable disease, and at least 1 previous treatment regimen of platinum/taxane chemotherapy. Patients received iniparib 8 mg/kg intravenously on days 1 and 4 weekly, with imaging every 8 weeks...
February 2016: International Journal of Gynecological Cancer
Catherine A Shu, Qin Zhou, Anjali R Jotwani, Alexia Iasonos, Mario M Leitao, Jason A Konner, Carol A Aghajanian
OBJECTIVE: Ovarian clear cell carcinomas (OCCCs) are rare, and uncertainty exists as to the optimal treatment paradigm and validity of the FIGO staging system, especially in early-stage disease. METHODS: We performed a retrospective cohort study of all OCCC patients diagnosed and treated at Memorial Sloan Kettering Cancer Center between January 1996 and December 2013. Progression-free survival (PFS) and overall survival (OS) were calculated by stage and race, and comparisons were made using the log-rank test...
November 2015: Gynecologic Oncology
David M Hyman, Alexandra E Snyder, Richard D Carvajal, John F Gerecitano, Martin H Voss, Alan L Ho, Jason Konner, Jennifer L Winkelmann, Megan A Stasi, Kelsey R Monson, Alexia Iasonos, David R Spriggs, Philip Bialer, Mario E Lacouture, Jerrold B Teitcher, Nora Katabi, Matthew G Fury
PURPOSE: Phosphatidylinositol-3-kinase I (PI3K) inhibition sensitizes a wide range of cancer cell lines to platinum/taxane-based chemotherapy. This phase I study combines buparlisib, a pan-class 1A PI3K inhibitor, with two schedules of carboplatin and paclitaxel for patients with advanced solid tumors (, NCT01297452). METHODS: There were two regimens: Group 1 received carboplatin AUC 5 and paclitaxel 175 mg/m(2), on day 1 of a 21-day cycle with pegfilgrastim support; Group 2 received carboplatin AUC 5 (day 1) and paclitaxel 80 mg/m(2) (days 1, 8, and 15) on a 28-day cycle without growth factor support...
April 2015: Cancer Chemotherapy and Pharmacology
Catherine A Shu, Jason A Konner
No abstract text is available yet for this article.
February 2015: Oncologist
Vaagn Andikyan, Fady Khoury-Collado, Samith Sandadi, William P Tew, Roisin E O'Cearbhaill, Jason A Konner, Yukio Sonoda, Richard R Barakat, Dennis S Chi, Nadeem R Abu-Rustum
OBJECTIVE: It is well documented that recurrence after pelvic exenteration remains high (up to 50%), and patients may require a prolonged period of recuperation following this aggressive surgery. We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. METHODS: We reviewed the medical records of patients with any gynecologic cancer who underwent exenterative surgery between January 2005 and February 2011 at our institution...
June 2013: International Journal of Gynecological Cancer
Paul Sabbatini, Takemasa Tsuji, Luis Ferran, Erika Ritter, Christine Sedrak, Kevin Tuballes, Achim A Jungbluth, Gerd Ritter, Carol Aghajanian, Katherine Bell-McGuinn, Martee L Hensley, Jason Konner, William Tew, David R Spriggs, Eric W Hoffman, Ralph Venhaus, Linda Pan, Andres M Salazar, Catherine Magid Diefenbach, Lloyd J Old, Sacha Gnjatic
PURPOSE: Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety and in vivo immunogenicity of synthetic overlapping long peptides (OLP) from a human tumor self-antigen, we conducted a phase I clinical trial with OLP from cancer-testis antigen NY-ESO-1 in various adjuvant combinations. EXPERIMENTAL DESIGN: Twenty-eight patients with advanced ovarian cancer in second or third remission were enrolled sequentially in three cohorts and received at least one vaccination...
December 1, 2012: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Rachel Nicole Grisham, Christina Adaniel, David M Hyman, Weining Ma, Alexia Iasonos, Carol Aghajanian, Jason Konner
BACKGROUND: Gemcitabine is active in several gynecologic malignancies including ovarian cancer, cervical cancer, and uterine leiomyosarcoma. It has been used in an off-label setting for the treatment of advanced endometrial cancer, despite lack of published data showing efficacy. We performed a retrospective study to determine the progression-free survival and response rate of endometrial cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center. METHODS: Eligible patients had histologically confirmed advanced (stage IV or recurrent) endometrial cancer that was treated with single-agent gemcitabine at Memorial Sloan-Kettering Cancer Center between 1999 and 2009...
June 2012: International Journal of Gynecological Cancer
Joyce N Barlin, Fanny Dao, Nadim Bou Zgheib, Sarah E Ferguson, Paul J Sabbatini, Martee L Hensley, Katherine M Bell-McGuinn, Jason Konner, William P Tew, Carol Aghajanian, Dennis S Chi
OBJECTIVE: GOG study 172 demonstrated improved progression-free (PFS) and overall (OS) survival for patients with stage III optimally debulked ovarian and peritoneal carcinoma treated with IV/IP paclitaxel and IP cisplatin compared to standard IV therapy. The inpatient administration, toxicity profile, and limited completion rate have been blamed for the lack of acceptance and widespread use of this regimen. We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen...
June 2012: Gynecologic Oncology
Yevgeniy Balagula, Alyx Rosen, Belinda H Tan, Klaus J Busam, Melissa P Pulitzer, Robert J Motzer, Darren R Feldman, Jason A Konner, Diane Reidy-Lagunes, Patricia L Myskowski, Mario E Lacouture
BACKGROUND: Dermatologic adverse events stemming from anticancer therapies have become an increasingly frequent clinical problem. Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored. METHODS: A retrospective analysis of patients who were referred to the Dermatology Service for diagnosis and management of rash in the setting of therapy with the mTOR inhibitors everolimus and temsirolimus was performed...
October 15, 2012: Cancer
Jason Konner, Rachel N Grisham, Jae Park, Owen A O'Connor, Gillian Cropp, Robert Johnson, Alison L Hannah, Martee L Hensley, Paul Sabbatini, Svetlana Mironov, Svetlana Miranov, Samuel Danishefsky, David Hyman, David R Spriggs, Jakob Dupont, Carol Aghajanian
PURPOSE: To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma. PATIENTS AND METHODS: Patients were treated weekly for 3 out of 4 weeks (Schedule A) or 2 out of 3 weeks (Schedule B) with KOS-862 (16-120 mg/m(2)). Pharmacokinetic (PK) sampling was performed during cycles 1 and 2; pharmacodynamic (PD) assessment for microtubule bundle formation (MTBF) was performed after the 1st dose, only at or above 100 mg/m(2)...
December 2012: Investigational New Drugs
Jason A Konner, Diana M Grabon, Scott R Gerst, Alexia Iasonos, Howard Thaler, Sandra D Pezzulli, Paul J Sabbatini, Katherine M Bell-McGuinn, William P Tew, Martee L Hensley, David R Spriggs, Carol A Aghajanian
PURPOSE: Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed. PATIENTS AND METHODS: Treatment was as follows: paclitaxel 135 mg/m(2) IV over 3 hours day 1, cisplatin 75 mg/m(2) IP day 2, and paclitaxel 60 mg/m(2) IP day 8...
December 10, 2011: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Edward J Tanner, Destin R Black, Oliver Zivanovic, Siobhan M Kehoe, Fanny Dao, Jason A Konner, Richard R Barakat, Stuart M Lichtman, Douglas A Levine
OBJECTIVE: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy. METHODS: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases...
January 2012: Gynecologic Oncology
Jason A Konner, Katherine M Bell-McGuinn, Paul Sabbatini, Martee L Hensley, William P Tew, Neeta Pandit-Taskar, Nicholas Vander Els, Martin D Phillips, Charles Schweizer, Susan C Weil, Steven M Larson, Lloyd J Old
PURPOSE: Folate receptor α expression is highly restricted in normal adult tissues but upregulated in a wide range of human cancer types, including epithelial ovarian cancer. Farletuzumab, a humanized monoclonal antibody against folate receptor α, has shown antitumor activity and favorable toxicity in preclinical evaluation. This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD). EXPERIMENTAL DESIGN: Patients with platinum-refractory or platinum-resistant epithelial ovarian cancer received farletuzumab (12...
November 1, 2010: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
John P Diaz, William P Tew, Oliver Zivanovic, Jason Konner, Paul J Sabbatini, Lisa A dos Santos, Nadeem R Abu-Rustum, Dennis S Chi, Carol Aghajanian, Richard R Barakat
OBJECTIVE: The objective of this study was to examine the incidence and management of bevacizumab-associated gastrointestinal (GI) perforations in patients with recurrent ovarian carcinoma. METHODS: We identified all patients who received bevacizumab off protocol from August 2004-August 2008. We examined their medical records for reports of confirmed GI perforation, associated clinicopathological factors, treatment, and outcomes. RESULTS: Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforations, with a median of 4 (range, 2-8) previous cytotoxic regimens...
March 2010: Gynecologic Oncology
Paul Sabbatini, David Spriggs, Carol Aghajanian, Martee Hensley, William Tew, Jason Konner, Kathryn Bell-McGuinn, Margrit Juretzka, Alexia Iasonos
PURPOSE.: To describe the characteristics of a series of study populations of ovarian cancer patients with identical eligibility criteria in second or subsequent clinical remission (cCR) and to propose endpoint benchmarks for future consolidation studies. PATIENTS AND METHODS.: The patient populations consisted of those (1) untreated (U; observed until progression; n=35, (2) receiving imatinib (G; n=32), (3) receiving goserelin and bicalutamide (A; n=32), and (4) receiving vaccine (V; n=68; total=167). The endpoint of the combined analysis was progression-free survival in second remission (PFS 2)...
January 2010: Gynecologic Oncology
Dennis S Chi, Rebecca Phaëton, Thomas J Miner, Steven V Kardos, John P Diaz, Mario M Leitao, Ginger Gardner, Jae Huh, William P Tew, Jason A Konner, Yukio Sonoda, Nadeem R Abu-Rustum, Richard R Barakat, David P Jaques
OBJECTIVE: To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer. METHODS: An institutional study was conducted from July 2002 to July 2003 to prospectively identify pts who underwent an operative or endoscopic procedure to palliate the symptoms of advanced cancer. This report focuses on pts with malignant bowel obstruction due to recurrent ovarian cancer...
August 2009: Oncologist
Martee L Hensley, Nicole Ishill, Robert Soslow, Joseph Larkin, Nadeem Abu-Rustum, Paul Sabbatini, Jason Konner, William Tew, David Spriggs, Carol A Aghajanian
OBJECTIVE: Patients with completely resected stages I-IV high grade uterine leiomyosarcoma are at high risk for recurrence. No adjuvant treatment has been shown to improve survival, although prospective data are limited. We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population. METHODS: Eligible patients were treated with gemcitabine 900 mg/m(2) over 90 min days 1 and 8 plus docetaxel 75 mg/m(2) day 8, every 3 weeks for 4 cycles...
March 2009: Gynecologic Oncology
Martee L Hensley, Joseph Larkin, Matthew Fury, Scott Gerst, D Fritz Tai, Paul Sabbatini, Jason Konner, Mauro Orlando, Tiana L Goss, Carol A Aghajanian
PURPOSE: To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer. EXPERIMENTAL DESIGN: Patients with no prior pemetrexed or gemcitabine therapy enrolled in cohorts of three, expanding to six if dose-limiting toxicity (DLT) was observed. Pemetrexed, escalated from to 700 mg/m(2), was given before gemcitabine 1,500 mg/m(2) every 14 days. DLTs were grade 4 neutropenia lasting >7 days or febrile neutropenia, grade 4 or 3 thrombocytopenia (with bleeding), grade > or =3 nonhematologic toxicity, or treatment delay of > or =1 week due to unresolved toxicity...
October 1, 2008: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Jason Konner, Russell J Schilder, Felicia A DeRosa, Scott R Gerst, William P Tew, Paul J Sabbatini, Martee L Hensley, David R Spriggs, Carol A Aghajanian
OBJECTIVE: Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer. METHODS: An initial intravenous [IV] dose of cetuximab (400 mg/m(2)) was administered over 120 min followed by weekly IV infusions of cetuximab (250 mg/m(2)) administered over 60 min. Paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] of 6) were administered IV every 21 days for 6 cycles. The order of administration was cetuximab followed by paclitaxel and then carboplatin...
August 2008: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"